Kidney Cancer - Pipeline Review, H1 2012

Global Markets Direct, January 2012, Pages: 284

Kidney Cancer – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Kidney Cancer - Pipeline Review, H1 2012', provides an overview of the Kidney Cancer therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Cancer. 'Kidney Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Kidney Cancer.
- A review of the Kidney Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Kidney Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Kidney Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Kidney Cancer pipeline depth and focus of Kidney Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Kidney Cancer Therapeutic Products under Development, Key Players in Kidney Cancer Therapeutics, Kidney Cancer Pipeline Overview, Kidney Cancer Pipeline, Kidney Cancer Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Kidney Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Kidney Cancer
Kidney Cancer Therapeutics under Development by Companies
Kidney Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Kidney Cancer Therapeutics – Products under Development by Companies
Kidney Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Kidney Cancer Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Seattle Genetics, Inc.
Genentech, Inc.
Merck & Co., Inc.
Emergent BioSolutions Inc.
Oxford BioMedica plc
Light Sciences Oncology, Inc.
Novartis AG
ImClone Systems Incorporated
Astellas Pharma Inc.
Eisai Co., Ltd.
Ono Pharmaceutical Co., Ltd.
OSI Pharmaceuticals, Inc.
Pfizer Inc.
Taiho Pharmaceutical Co., Ltd.
Exelixis, Inc.
Alfacell Corporation
Celgene Corporation
Bayer AG
MannKind Corporation
3SBio Inc.
EntreMed, Inc.
Celldex Therapeutics, Inc.
Active Biotech AB
AEterna Zentaris Inc.
AIDA Pharmaceuticals, Inc.
Lorus Therapeutics Inc
Bionomics Limited
Northwest Biotherapeutics, Inc.
Cleveland BioLabs, Inc.
Patrys Limited
Keryx Biopharmaceuticals, Inc.
ARQULE, INC
Allos Therapeutics, Inc
Flamel Technologies S.A.
Dendreon Corporation
Green Cross Corporation
MOLOGEN AG
OncoTherapy Science, Inc.
Threshold Pharmaceuticals, Inc.
Innate Pharma SA
Protox Therapeutics Inc.
Rexahn Pharmaceuticals, Inc.
Debiopharm Group
Antisense Pharma GmbH
Wilex AG
Philogen S.p.A.
Cadila Pharmaceuticals Ltd.
ERYtech Pharma
immatics biotechnologies GmbH
Curacyte AG
Argos Therapeutics, Inc.
Cytheris SA
Altor BioScience Corporation
AgrenVec, S.L.
Alethia Biotherapeutics Inc.
Gene Signal International SA.
MacroGenics, Inc.
Pivotal BioSciences, Inc.
Neotropix, Inc.
Jennerex Biotherapeutics, Inc.
Endocyte, Inc.
Advenchen Laboratories, LLC
Immutep S.A.
Syndax Pharmaceuticals, Inc.
Esperance Pharmaceuticals, Inc.
Welichem Biotech Inc.
Tigris Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc.
KAHR medical Ltd.
Advanced Cancer Therapeutics
Medical Enzymes AG
IkerChem S.L.
Immunovative Therapies, Ltd.
Kidney Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Nexavar - Drug Profile
Axitinib - Drug Profile
Axitinib - Drug Profile
Sutent - Drug Profile
ANYARA - Drug Profile
IMA901 - Drug Profile
TroVax - Drug Profile
NuLeusin - Drug Profile
Tivozanib - Drug Profile
Rencarex - Drug Profile
Dovitinib - Drug Profile
Aldesleukin for Kidney Cancer - Drug Profile
Aldesleukin + Recombinant interferon alfa + Fluorouracil - Drug Profile
Bevacizumab + Torisel - Drug Profile
Gemcitabine + Cisplatin + Bevacizumab - Drug Profile
Interferon Alfa-2B + Bevacizumab - Drug Profile
Interferon Alfa-2B - Drug Profile
BAY43-9006 - Drug Profile
Sunitinib - Drug Profile
Dactinomycin + Doxorubicin + Vincristine - Drug Profile
Sorafenib Tosylate - Drug Profile
Recombinant Interferon Alfa + Isotretinoin - Drug Profile
Interferon Alfa + CCI-779 - Drug Profile
BCG Vaccine + Iressa - Drug Profile
Interleukin-2 - Drug Profile
Dactinomycin + Filgrastim + Cylophosphamide + Doxorubicin hydrochloride + Etoposide + Vincristine sulfate + Radiation therapy - Drug Profile
RAD001 - Drug Profile
TroVax + IL-2 - Drug Profile
Interferon-Alpha + Interleukin-2 + 5-Fluorouracil - Drug Profile
Filgrastim + Doxorubicin + Ifosfamide - Drug Profile
Interferon-Alpha - Drug Profile
Votrient - Drug Profile
Everolimus + Bevacizumab - Drug Profile
ANYARA + Interferon Alpha - Drug Profile
Sunitinib - Drug Profile
Interferon-alpha - Drug Profile
Interleukin 2 + Interferon-alpha2 - Drug Profile
Dactinomycine + Doxorubicin + Vincristine + Radiation Therapy - Drug Profile
Sorafenib - Drug Profile
Sorafenib + Sunitinib - Drug Profile
bevacizumab + recombinant interferon alfa - Drug Profile
Carboplatin + Methotrexate + Vinblastine - Drug Profile
aldesleukin + recombinant interferon alfa + fluorouracil - Drug Profile
Dactinomycin + Carboplatin + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Vincristine Sulfate - Drug Profile
Doxorubicin hydrochloride - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
Sunitinib - Drug Profile
Recombinant Gamma Interferon - Drug Profile
Cisplatin + Radiation Therapy - Drug Profile
Sunitinib - Drug Profile
Bevacizumab + Interferon Alfa-2a - Drug Profile
Kidney Cancer Therapeutics – Drug Profile Updates
Kidney Cancer Therapeutics – Discontinued Products
Kidney Cancer Therapeutics - Dormant Products
Kidney Cancer – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Kidney Cancer, H1 2012
Products under Development for Kidney Cancer – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)
Number of Products under Development by Companies, H1 2012 (Contd..4)
Number of Products under Development by Companies, H1 2012 (Contd..5)
Number of Products under Development by Companies, H1 2012 (Contd..6)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..9)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..10)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Development by Companies, H1 2012 (Contd..4)
Products under Development by Companies, H1 2012 (Contd..5)
Products under Development by Companies, H1 2012 (Contd..6)
Products under Development by Companies, H1 2012 (Contd..7)
Products under Development by Companies, H1 2012 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..15)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..16)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..17)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..18)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..19)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..20)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..21)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..22)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..23)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..24)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..25)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..26)
Bristol-Myers Squibb Company, H1 2012
Genzyme Corporation, H1 2012
Boehringer Ingelheim GmbH, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Kyowa Hakko Kirin Co., Ltd., H1 2012
Amgen Inc., H1 2012
AstraZeneca PLC, H1 2012
Eli Lilly and Company, H1 2012
GlaxoSmithKline plc, H1 2012
Seattle Genetics, Inc., H1 2012
Genentech, Inc., H1 2012
Merck & Co., Inc., H1 2012
Emergent BioSolutions Inc., H1 2012
Oxford BioMedica plc, H1 2012
Light Sciences Oncology, Inc., H1 2012
Novartis AG, H1 2012
ImClone Systems Incorporated, H1 2012
Astellas Pharma Inc., H1 2012
Eisai Co., Ltd., H1 2012
Ono Pharmaceutical Co., Ltd., H1 2012
OSI Pharmaceuticals, Inc., H1 2012
Pfizer Inc., H1 2012
Taiho Pharmaceutical Co., Ltd., H1 2012
Exelixis, Inc., H1 2012
Alfacell Corporation, H1 2012
Celgene Corporation, H1 2012
Bayer AG, H1 2012
MannKind Corporation, H1 2012
3SBio Inc., H1 2012
EntreMed, Inc., H1 2012
Celldex Therapeutics, Inc., H1 2012
Active Biotech AB, H1 2012
AEterna Zentaris Inc., H1 2012
AIDA Pharmaceuticals, Inc., H1 2012
Lorus Therapeutics Inc, H1 2012
Bionomics Limited, H1 2012
Northwest Biotherapeutics, Inc., H1 2012
Cleveland BioLabs, Inc., H1 2012
Patrys Limited, H1 2012
Keryx Biopharmaceuticals, Inc., H1 2012
ARQULE, INC, H1 2012
Allos Therapeutics, Inc, H1 2012
Flamel Technologies S.A., H1 2012
Dendreon Corporation, H1 2012
Green Cross Corporation, H1 2012
MOLOGEN AG, H1 2012
OncoTherapy Science, Inc., H1 2012
Threshold Pharmaceuticals, Inc., H1 2012
Innate Pharma SA, H1 2012
Protox Therapeutics Inc., H1 2012
Rexahn Pharmaceuticals, Inc., H1 2012
Debiopharm Group, H1 2012
Antisense Pharma GmbH, H1 2012
Wilex AG, H1 2012
Philogen S.p.A., H1 2012
Cadila Pharmaceuticals Ltd., H1 2012
ERYtech Pharma, H1 2012
immatics biotechnologies GmbH, H1 2012
Curacyte AG, H1 2012
Argos Therapeutics, Inc., H1 2012
Cytheris SA, H1 2012
Altor BioScience Corporation, H1 2012
AgrenVec, S.L., H1 2012
Alethia Biotherapeutics Inc., H1 2012
Gene Signal International SA., H1 2012
MacroGenics, Inc., H1 2012
Pivotal BioSciences, Inc., H1 2012
Neotropix, Inc., H1 2012
Jennerex Biotherapeutics, Inc., H1 2012
Endocyte, Inc., H1 2012
Advenchen Laboratories, LLC, H1 2012
Immutep S.A., H1 2012
Syndax Pharmaceuticals, Inc., H1 2012
Esperance Pharmaceuticals, Inc., H1 2012
Welichem Biotech Inc., H1 2012
Tigris Pharmaceuticals, Inc., H1 2012
AVEO Pharmaceuticals, Inc., H1 2012
KAHR medical Ltd., H1 2012
Advanced Cancer Therapeutics, H1 2012
Medical Enzymes AG, H1 2012
IkerChem S.L., H1 2012
Immunovative Therapies, Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Kidney Cancer Therapeutics – Drug Profile Updates
Kidney Cancer Therapeutics – Discontinued Products
Kidney Cancer Therapeutics – Discontinued Products (Contd..1)
Kidney Cancer Therapeutics – Discontinued Products (Contd..2)
Kidney Cancer Therapeutics – Discontinued Products (Contd..3)
Kidney Cancer Therapeutics – Dormant Products
Kidney Cancer Therapeutics – Dormant Products (Contd..1)
Kidney Cancer Therapeutics – Dormant Products (Contd..2)
Kidney Cancer Therapeutics – Dormant Products (Contd..3)
Kidney Cancer Therapeutics – Dormant Products (Contd..4)
Kidney Cancer Therapeutics – Dormant Products (Contd..5)
Kidney Cancer Therapeutics – Dormant Products (Contd..6)
Kidney Cancer Therapeutics – Dormant Products (Contd..7)
Kidney Cancer Therapeutics – Dormant Products (Contd..8)
Kidney Cancer Therapeutics – Dormant Products (Contd..9)
Kidney Cancer Therapeutics – Dormant Products (Contd..10)
Kidney Cancer Therapeutics – Dormant Products (Contd..11)
Kidney Cancer Therapeutics – Dormant Products (Contd..12)
Kidney Cancer Therapeutics – Dormant Products (Contd..13)
Kidney Cancer Therapeutics – Dormant Products (Contd..14)
Kidney Cancer Therapeutics – Dormant Products (Contd..15)
Kidney Cancer Therapeutics – Dormant Products (Contd..16)
Kidney Cancer Therapeutics – Dormant Products (Contd..17)
Kidney Cancer Therapeutics – Dormant Products (Contd..18)
Kidney Cancer Therapeutics – Dormant Products (Contd..19)
Kidney Cancer Therapeutics – Dormant Products (Contd..20)

List of Figures
Number of Products under Development for Kidney Cancer, H1 2012
Products under Development for Kidney Cancer – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2013
• Rheumatoid Arthritis - Pipeline Review, H1 2013
• Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2013
• Alzheimer's Disease – Pipeline Review, H1 2013
• Hepatitis - Pipeline Review, H1 2013
• Neuropathic Pain - Pipeline Review, H1 2013
• Prostate Cancer - Pipeline Review, H1 2013
• HIV / AIDS – Pipeline Review, H1 2013
• Obesity - Pipeline Review, H1 2013
• Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2013